Many groundbreaking scientific discoveries never reach patients because they fail to attract capital or secure a commercial partnership. This "translation death" highlights that business development, not just R&D, is a critical bottleneck in delivering therapies to patients.

An economic analysis modeling a 40% smaller NIH budget from 1980-2007 found that foundational science supporting major drugs like Gilead's HIV meds and Novartis's Gleevec would not have been funded. This provides a stark, data-driven warning about the long-term innovation cost of current budget cut proposals.

A shocking statistic reveals the median age of an intramural researcher at the National Institutes of Health (NIH) is 71. This highlights a deep institutional problem where the system fails to create opportunities for young scientists, stifling innovation and new ideas.

The greatest threat to US innovation is not simply cutting NIH funding, but imposing political litmus tests on which research gets funded. This mirrors the disastrous Lysenkoism of the Soviet Union, where political ideology replaced the scientific method, guaranteeing the destruction of true innovation.

The foundational U.S. science policy was created in 1945 when the government funded 70% of all R&D. Today, that ratio has inverted, with industry funding 70%. This dramatic shift requires a new government strategy focused on funding only the basic, pre-competitive research that the private sector won't.

Despite scientific breakthroughs and better technology, the cost per approved drug has steadily increased over the last 60 years. This phenomenon, the reverse of Moore's Law, is called Eroom's Law and highlights a fundamental productivity problem in the biopharma industry, with costs approaching $1B+ per successful drug.

The public and politicians expect scientific funding to yield guaranteed results. This forces a focus on safe, incremental research. To achieve major breakthroughs for issues like climate change, society must understand that failure is a vital part of the scientific process and be willing to fund high-risk, high-reward 'gamble' projects.

To combat scientific stagnation, the government is launching 'meta-science' units to experiment with funding. One trial, 'golden tickets,' allows individual peer reviewers to unilaterally fund bold, high-risk ideas, mirroring how VCs back outlier founders.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.